Current Limitations and Perspectives of Chimeric Antigen Receptor-T-Cells in Acute Myeloid Leukemia

Area of Science:

• Hematologic oncology
• Immunotherapy
• Cellular therapy

Background:

• Chimeric antigen receptor (CAR)-T-cell therapy is a potent immunotherapy for hematologic cancers.
• Identifying ideal target antigens for CAR-T-cell therapy in acute myeloid leukemia (AML) is crucial, requiring high expression on leukemic cells and minimal expression on healthy tissues.
• Clinical application of CAR-T-cell therapy in AML is limited, with a need to eradicate leukemic stem cells (LSCs) and ensure hematopoietic recovery.

Purpose of the Study:

• To critically review current CAR-T-cell target antigens and products for AML.
• To assess challenges hindering the clinical translation and routine implementation of CAR-T-cell therapy in AML.
• To explore perspectives and strategies for overcoming these challenges.

Main Methods:

• Literature review of preclinical and clinical studies on CAR-T-cell therapy in AML.
• Analysis of candidate target antigens based on expression profiles on leukemic and healthy hematopoietic cells.
• Evaluation of challenges in CAR-T-cell product development and clinical application.

Main Results:

• Several target antigens are under investigation for AML CAR-T-cell therapy.
• Significant challenges exist in achieving target specificity, ensuring safety, and managing clinical logistics for CAR-T-cell therapy in AML.
• Limited clinical experience necessitates further research and development.

Conclusions:

• Optimizing CAR-T-cell therapy for AML requires careful selection of target antigens and addressing key translational hurdles.
• Overcoming challenges in antigen targeting, safety, and clinical implementation is essential for realizing the full potential of CAR-T-cell therapy in AML.
• Future research should focus on developing effective CAR-T-cell strategies that ensure durable remission and hematopoietic recovery in AML patients.